BACKGROUND: Symptom cluster research is an emerging field in symptom management. The ability to identify symptom clusters that are specific to pediatric oncology patients may lead to improved understanding of symptoms' underlying mechanisms among patients of all ages. OBJECTIVE: The purpose of this study, in a sample of children and adolescents with cancer who underwent a cycle of myelosuppressive chemotherapy, was to compare the number and types of symptom clusters identified using patients' ratings of symptom occurrence and symptom severity. METHODS: Children and adolescents with cancer (10-18 years of age; N = 131) completed the Memorial Symptom Assessment Scale 10-18 on the day they started a cycle of myelosuppressive chemotherapy, using a 1-week recall of experiences. Symptom data based on occurrence and severity ratings were examined using exploratory factor analysis. The defined measurement model suggested by the best exploratory factor analysis model was then examined with a latent variable analysis. RESULTS: Three clusters were identified when symptom occurrence ratings were evaluated, which were classified as a chemotherapy sequela cluster, mood disturbance cluster, and a neuropsychological discomfort cluster. Analysis of symptom severity ratings yielded similar cluster configurations. CONCLUSIONS: Cluster configurations remained relatively stable between symptom occurrence and severity ratings. The evaluation of patients at a common point in the chemotherapy cycle may have contributed to these findings. IMPLICATIONS FOR PRACTICE: Additional uniformity in symptom clusters investigations is needed to allow appropriate comparisons among studies. The dissemination of symptom cluster research methodology through publication and presentation may promote uniformity in this field.
BACKGROUND: Symptom cluster research is an emerging field in symptom management. The ability to identify symptom clusters that are specific to pediatric oncology patients may lead to improved understanding of symptoms' underlying mechanisms among patients of all ages. OBJECTIVE: The purpose of this study, in a sample of children and adolescents with cancer who underwent a cycle of myelosuppressive chemotherapy, was to compare the number and types of symptom clusters identified using patients' ratings of symptom occurrence and symptom severity. METHODS:Children and adolescents with cancer (10-18 years of age; N = 131) completed the Memorial Symptom Assessment Scale 10-18 on the day they started a cycle of myelosuppressive chemotherapy, using a 1-week recall of experiences. Symptom data based on occurrence and severity ratings were examined using exploratory factor analysis. The defined measurement model suggested by the best exploratory factor analysis model was then examined with a latent variable analysis. RESULTS: Three clusters were identified when symptom occurrence ratings were evaluated, which were classified as a chemotherapy sequela cluster, mood disturbance cluster, and a neuropsychological discomfort cluster. Analysis of symptom severity ratings yielded similar cluster configurations. CONCLUSIONS: Cluster configurations remained relatively stable between symptom occurrence and severity ratings. The evaluation of patients at a common point in the chemotherapy cycle may have contributed to these findings. IMPLICATIONS FOR PRACTICE: Additional uniformity in symptom clusters investigations is needed to allow appropriate comparisons among studies. The dissemination of symptom cluster research methodology through publication and presentation may promote uniformity in this field.
Authors: Philip J Landrigan; Leonardo Trasande; Lorna E Thorpe; Charon Gwynn; Paul J Lioy; Mary E D'Alton; Heather S Lipkind; James Swanson; Pathik D Wadhwa; Edward B Clark; Virginia A Rauh; Frederica P Perera; Ezra Susser Journal: Pediatrics Date: 2006-11 Impact factor: 7.124
Authors: Christine Miaskowski; Andrea Barsevick; Ann Berger; Rocco Casagrande; Patricia A Grady; Paul Jacobsen; Jean Kutner; Donald Patrick; Lani Zimmerman; Canhua Xiao; Martha Matocha; Sue Marden Journal: J Natl Cancer Inst Date: 2017-01-24 Impact factor: 13.506
Authors: Tyler W Buckner; Jichuan Wang; Darren A DeWalt; Shana Jacobs; Bryce B Reeve; Pamela S Hinds Journal: Pediatr Blood Cancer Date: 2014-03-15 Impact factor: 3.167
Authors: Rebecca Williamson Lewis; Karen E Effinger; Karen Wasilewski-Masker; Ann Mertens; Canhua Xiao Journal: Support Care Cancer Date: 2021-07-06 Impact factor: 3.603
Authors: Anna Spathis; Sara Booth; Sarah Grove; Helen Hatcher; Isla Kuhn; Stephen Barclay Journal: J Adolesc Young Adult Oncol Date: 2015-03 Impact factor: 2.223
Authors: Melisa L Wong; Bruce A Cooper; Steven M Paul; Jon D Levine; Yvette P Conley; Fay Wright; Marilyn Hammer; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2017-05-19 Impact factor: 3.612
Authors: Carmen Ward Sullivan; Heather Leutwyler; Laura B Dunn; Bruce A Cooper; Steven M Paul; Yvette P Conley; Jon D Levine; Christine A Miaskowski Journal: Eur J Oncol Nurs Date: 2017-04-26 Impact factor: 2.398
Authors: Claire J Han; Kerryn Reding; Bruce A Cooper; Steven M Paul; Yvette P Conley; Marilyn Hammer; Fay Wright; Frances Cartwright; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2019-05-09 Impact factor: 3.612
Authors: Sarah L Kerns; Chunkit Fung; Patrick O Monahan; Shirin Ardeshir-Rouhani-Fard; Mohammad I Abu Zaid; AnnaLynn M Williams; Timothy E Stump; Howard D Sesso; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair Beard; Robert A Huddart; Jeri Kim; Christian Kollmannsberger; Deepak M Sahasrabudhe; Ryan Cook; Sophie D Fossa; Lawrence H Einhorn; Lois B Travis Journal: J Clin Oncol Date: 2018-04-04 Impact factor: 44.544